Chiffre d'affaires Takeda Pharmaceutical — Rapport annuel et faits saillants financiers

Creating better health for people and a brighter future for the world is our purpose. The science and technology we advance are constantly evolving. But through our enduring values, our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while creating an exceptional experience for our people.

Message du CEO et orientation stratégique

Dear Takeda Shareholders, Fiscal year 2025 is a pivotal year for Takeda, as we advance our late-stage pipeline and prepare to launch new products that will be future drivers of our sustainable growth. In the first half of the fiscal year, we presented very positive Phase 3 data for two assets in our late-stage pipeline. First was rusfertide, a treatment for polycythemia vera, a rare blood cancer that increases the risk of life-threatening cardiovascular and thrombotic events. Then came oveporexton, a treatment for narcolepsy type 1, a neurological disorder that causes excessive daytime sleepiness and disrupted nighttime sleep. Both pipeline assets are scheduled for regulatory submission by the end of this fiscal year and, if approved, they have the potential to provide new treatment options for patients. Additionally, for our oral allosteric tyrosine kinase 2 (TYK2) inhibitor zasocitinib, we anticipate readouts for two Phase 3 studies in psoriasis before the end of this fiscal year.

Pipeline de développement et valeur potentielle

Fiscal year 2025 is a year of transformation, as we drive innovation at an unprecedented speed and scale. To bring new treatment options to patients around the world, we are focusing on the advancement of six late-stage pipeline programs and accelerating investments in preparation for their launch. We have a robust portfolio of promising late-stage assets approaching commercialization. Regulatory filings for rusfertide and oveporexton are expected in the second half of the fiscal year, as well as Phase 3 results for zasocitinib. This progress enables us to potentially deliver new, innovative treatments to patients and serves as a cornerstone of Takeda’s growth strategy, reflecting our dedication to advancing the future of health care. Each of the six late-stage programs holds the potential to transform patients’ lives. With our deep expertise in understanding disease biology and our commitment to addressing unmet medical needs, we aim to redefine the standard of care.

Oveporexton - indication, besoins non satisfaits et résultats

Indication being studied: Narcolepsy Type 1 (NT1). NT1 is a chronic, rare neurological disorder caused by a significant loss of orexin neurons. Current treatments do not address the root cause of NT1 and provide only partial improvements with >80% of survey respondents reported experiencing residual symptoms1. The orexin neuropeptide is essential to sleep-wake and other disorders where orexin signaling is implicated. NT1 is characterized by excessive daytime sleepiness, disrupted nighttime sleep, hallucinations, sleep paralysis and cataplexy (sudden loss of muscle tone) 2.

Takeda is the world’s leader in orexin science with the most comprehensive development program. Oveporexton, discovered in our labs in Shonan, Japan, is an investigative oral orexin receptor 2-selective agonist designed to address the root cause of NT1. Both Phase 3 studies met all primary and secondary endpoints, demonstrating statistically significant improvements compared to placebo across a broad range of symptoms at all dose levels at week 12. Consistent with all oveporexton studies to date, no serious treatment-related adverse events were reported. These results reinforce the potential of oveporexton to unlock a new era of care in NT1.

Lire aussi: Auto-entrepreneur : Chiffre d'affaires maximum

Performances financières - points clés du premier semestre FY2025

FY2025 H1 Financial HighlightsRevenue by region*Convenience translation has been made at an exchange rate of 1 USD = 147.97JPY.

In the first half of fiscal year 2025, Growth & Launch Products delivered revenue of 1,143.0 billion yen, marking a 5.3% increase on a constant exchange rate (CER) basis. Growth for ENTYVIO® for ulcerative colitis and Crohn’s disease was +5.1% on a CER basis. Revenue of EOHILIA® for eosinophilic esophagitis grew by 98.4% on a CER basis with patient demand growing month over month since its launch in February 2024.

Mises à jour commerciales par domaines clés

Hereditary angioedema treatment TAKHZYRO®, which grew by 5.9% on a CER basis, continues to deliver sustained global growth with approximately 6,700 patients treated worldwide. market penetration and rapid geographic expansion with the recent launch in Japan and national reimbursement inclusion in China. Immunoglobulin grew 3.1% and Albumin declined 2.4% at CER, impacted by shipment timing and quarterly phasing. Demand remains strong, and we confirm our full year guidance of mid-single digit growth at CER for the PDT portfolio.

The Oncology portfolio delivered steady growth across key brands, including FRUZAQLA®, which has been approved or launched in more than 30 countries to date. Key drivers for FRUZAQLA include the need for new non-chemotherapy treatment option in metastatic colorectal cancer. ADCETRIS® growth (+11.5% at CER) is primary driven by continued increased use in first-line Hodgkin lymphoma. Global demand for QDENGA®, for the prevention of dengue, remains strong, with the vaccine now available in 31 countries, driving additional growth through increasing breadth and depth in these markets and further geographic expansion.

Impacts, ajustements et perspectives financières

Revenue declined 57.7% at CER in first half of fiscal year 2025, reflecting broader availability of generic supply. Our updates to our forecast reflect a reduction in sales forecasts for products including ENTYVIO and VYVANSE, impairment losses on intangible assets and transactional FX headwinds as well as a higher tax rate, partially offset by savings from OPEX management efforts. Our updates to our Management Guidance primarily reflect transactional FX headwinds with higher OPEX savings expected to fully mitigate unfavorable change in product mix.

Lire aussi: Auto-Entrepreneur en France : Plafonds

Mesures financières et information non-IFRS

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). This presentation and materials distributed in connection with this presentation include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of Takeda’s FY2025 H1 investor presentation.

Engagements, gouvernance et développement durable

Our approach to sustainability is summarized in our commitments to Patients, our People, the Planet, and Values-based Governance. Upholding these commitments strengthens our ability to discover and deliver life-transforming treatments, business resilience and ability to create long-term value. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet.

We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. Through bold investments in digital, data, and AI-driven capabilities, our teams are delivering for patients at speed and scale. We’ve entered a new era for health and for Takeda.

International Financial Group Limited | Our corporate video

Informations prospectives et mentions légales

This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. Takeda does not undertake to update any of the forward-looking statements contained in this presentation or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this presentation may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. References in this presentation to peak revenue ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur.

Informations médicales et disponibilité des produits

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. This presentation and materials were filed with the Securities and Exchange Commission (the “SEC”) on June 25, 2025.

Lire aussi: Seuil et Exonérations CFE Auto-Entrepreneur

Documents liés et ressources investisseurs

Annual Integrated Report 2026Takeda’s 2026 Annual Integrated Report summarizes the progress we made in FY2025 and how we’re building momentum and resilience in our growth journey as we deliver on our purpose to create better health for people and a brighter future for the world. Our Commitments and FY2025 Highlights. Our Values in Action: Feature Stories.

Sign up for investor newsletterStay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planetSIGN UPExploreImportant notices

balises:

Articles populaires: